PRStrategy
From Clinical to Commercial Company: Enhanced Visibility for FDA Approval & Launch
National, Commercial, Public
TG Therapeutics was awaiting FDA Accelerated Approval for its one of kind inhibitor of PI3K-delta and CK-1 epsilon, Ukoniq (umbralisib), for two rare oncology indications, MZL and FL. This was TG’s first approval and would propel the company from a clinical stage to a commercial organization. This product is being evaluated for additional oncology indications in combination with other TG investigational products and industry approved products
LHS Solution
- In preparation for approval, LHS built communications strategy that created relationships with distinguished media outlets and refined ways to convey the drug’s value
- Leveraged Lymphoma KOLs to foster excitement and credibility
- Developed supporting material including disease, product-specific fact sheets and images
- Developed a multimedia press release to increase visibility and engagement
- Deployed social media with Twitter and LinkedIn channels to build awareness and influence key stakeholders
Results
- Strong media coverage consisting of 25 featured and 1251 syndicated and pickup articles with over 500 M audience reach
- Company attained 33% share of voice compared to its competitors
- Key coverage obtained in business, financial, pharma/biotech industry, and medical media outlets such as; Endpoints, Fierce, BioWorld, NASDAQ, Targeted Oncology, Med Page Today and OncLive
